IRIS
Fiorino, Gionata
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.861
AS - Asia 3.610
EU - Europa 1.796
SA - Sud America 1.318
AF - Africa 326
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 8
Totale 15.941
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.698
SG - Singapore 2.073
BR - Brasile 1.118
CN - Cina 696
FI - Finlandia 413
VN - Vietnam 341
IE - Irlanda 273
NG - Nigeria 223
DE - Germania 192
IT - Italia 168
FR - Francia 155
GB - Regno Unito 140
NL - Olanda 110
CA - Canada 109
HK - Hong Kong 106
SE - Svezia 102
AR - Argentina 72
IN - India 62
TR - Turchia 55
RU - Federazione Russa 45
EC - Ecuador 44
IL - Israele 40
BD - Bangladesh 37
UA - Ucraina 37
ES - Italia 34
BE - Belgio 33
ID - Indonesia 32
MX - Messico 31
IQ - Iraq 27
JP - Giappone 25
ZA - Sudafrica 25
EG - Egitto 21
PY - Paraguay 21
AU - Australia 18
CO - Colombia 18
CZ - Repubblica Ceca 18
CL - Cile 16
DZ - Algeria 16
IR - Iran 13
MA - Marocco 13
PL - Polonia 13
UZ - Uzbekistan 12
KE - Kenya 11
KZ - Kazakistan 11
PK - Pakistan 11
VE - Venezuela 11
PT - Portogallo 9
RO - Romania 9
AE - Emirati Arabi Uniti 8
KR - Corea 8
LT - Lituania 8
PE - Perù 8
SA - Arabia Saudita 8
UY - Uruguay 8
AZ - Azerbaigian 7
DO - Repubblica Dominicana 5
GR - Grecia 5
NP - Nepal 5
QA - Qatar 5
TN - Tunisia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BB - Barbados 4
NO - Norvegia 4
SY - Repubblica araba siriana 4
AL - Albania 3
AT - Austria 3
BA - Bosnia-Erzegovina 3
BN - Brunei Darussalam 3
BY - Bielorussia 3
EU - Europa 3
GE - Georgia 3
GT - Guatemala 3
HN - Honduras 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
SN - Senegal 3
BF - Burkina Faso 2
BO - Bolivia 2
BW - Botswana 2
CH - Svizzera 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
ET - Etiopia 2
HR - Croazia 2
JM - Giamaica 2
KH - Cambogia 2
LV - Lettonia 2
MD - Moldavia 2
MY - Malesia 2
OM - Oman 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
BG - Bulgaria 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
HU - Ungheria 1
JO - Giordania 1
KG - Kirghizistan 1
Totale 15.930
Salva come PNG Salva come JPEG
Città #
Wilmington 1.555
Chandler 1.247
Singapore 712
San Mateo 589
The Dalles 573
Dallas 494
Ann Arbor 437
Shanghai 423
Helsinki 410
Leawood 287
Lawrence 273
Princeton 273
Dublin 267
Ashburn 265
Boardman 230
Benin City 222
New York 179
Fairfield 152
Woodbridge 152
Paris 144
Beijing 142
Ho Chi Minh City 137
Hong Kong 103
São Paulo 99
Amsterdam 90
Toronto 81
Hanoi 71
London 67
Milan 54
Norwalk 47
Rio de Janeiro 47
Seattle 41
Kocaeli 40
Los Angeles 40
Columbus 38
Brussels 31
Phoenix 31
Council Bluffs 30
Santa Clara 30
Monmouth Junction 28
San Diego 28
Redwood City 26
Brasília 24
Munich 20
Curitiba 19
Guayaquil 19
Abbiategrasso 16
Belo Horizonte 16
Cambridge 16
Campinas 16
Haiphong 16
Pune 16
Brno 14
Chicago 12
Porto Alegre 12
Tokyo 12
Warsaw 12
Baghdad 11
Goiânia 11
Guarulhos 11
Johannesburg 11
Nairobi 11
Biên Hòa 10
Brooklyn 10
Cairo 10
Houston 10
Rome 10
Tashkent 10
Boston 9
Moscow 9
Sacramento 9
Santo André 9
Collegeville 8
Hải Dương 8
Jakarta 8
Lisbon 8
Nova Friburgo 8
Piracicaba 8
Quito 8
Redmond 8
Salvador 8
Volta Redonda 8
Warrington 8
Bury 7
Can Tho 7
Des Moines 7
Dhaka 7
Duncan 7
Falkenstein 7
Frankfurt am Main 7
Montes Claros 7
Montreal 7
Reston 7
Sorocaba 7
St Louis 7
Stockholm 7
Sydney 7
Taboão da Serra 7
Asunción 6
Baku 6
Totale 10.781
Salva come PNG Salva come JPEG
Nome #
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications 301
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 124
Adalimumab in ulcerative colitis: hypes and hopes 116
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis 107
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 103
A Prospective Comparison Between 1.5t Magnetic Resonance and 3t Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience 102
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission : a case report 98
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease 97
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 95
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD 93
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study 92
Risk of postoperative recurrence and postoperative management of Crohn's disease 90
Adalimumab in Crohn's disease : tips and tricks after 5 years of clinical experience 89
A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis 89
Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial 88
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis 88
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX (TM) and Tailored Delivery to the Gut 87
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 86
Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps 86
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study 85
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 85
Effect of Immunosuppression on Immune Response to Pneumococcal Vaccine in Inflammatory Bowel Disease: A Prospective Study 82
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 80
A PROLONGED FOLLOW-UP ON THE EFFICACY AND SAFETY OF INFLIXIMAB BIOSIMILAR CT-P13 IN IBD ACROSS ITALY: THE PROSIT COHORT 80
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 79
Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease 79
Perception of reproductive health in women with inflammatory bowel disease 79
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. 79
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 78
Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study 78
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 78
A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY ASSESSING THE EFFECTIVENESS OF BUDESONIDE MMX® FOR MILD-TO-MODERATE ULCERATIVE COLITIS 78
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 77
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 77
‘Quality of care’ standards in inflammatory bowel disease: A systematic review 77
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 76
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice 76
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 75
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 75
Contrast-enhancement at magnetic resonance enterography does not differentiate between fibrosis and inflammation in Crohn's disease: a prospective cohort study 75
Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? 75
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease : a prospective study 75
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis of Randomized Controlled Trials 74
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 74
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 73
Adalimumab for the treatment of pediatric Crohn's disease 72
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease 72
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome 71
JAK inhibitors: Novel developments in management of ulcerative colitis 71
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases 71
Are Surgical Rates Decreasing in the Biological Era In IBD? 71
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 70
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 70
ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease Part 2. IBD scores and general principles and technical aspects 70
Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn's disease: a tertiary centre real-life experience 69
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 69
Emerging therapeutic targets and strategies in Crohn's disease 68
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 68
A HEALTH TECHNOLOGY-RELATED COST DESCRIPTION CONCERNING ITALIAN IBD CENTRES DEALING WITH CROHN'S DISEASE: RESULTS FROM SOLE STUDY 68
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease : a case-matched analysis 68
OP018 High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling 67
Infliximab Inhibits Mucosal Pathological Angiogenesis in Crohn's Disease 67
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 66
Familial aggregation in inflammatory bowel disease: Is it genes or environment? 66
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease 66
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 65
Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation 64
Commentary: adjunct antibiotic combination therapy for ulcerative colitis - is it time to investigate Fusobacterium varium? 63
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target 63
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile 62
Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside 62
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease 62
Videocapsule endoscopy in portal hypertension: Seek till you find 62
VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY AND MODULATES SERUM AND AUTONOMIC BIOMARKERS IN BIOLOGICREFRACTORY CROHN'S DISEASE 62
STIMULATION OF CYP450-MEDIATED omega-3 DOCOSAHEXAENOIC ACID (DHA) METABOLISM VIA MFSD2A AS A NOVEL THERAPY FOR INFLAMMATORY BOWEL DISEASE 62
Safety of a (H1N1)V Vaccine in patients with inflammatory bowel disease treated with immunomodulators and biologicals 62
Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target 62
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? 61
Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease 61
Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy 61
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 60
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease 60
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis 60
Stimulation of CYP450-mediated omega-3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel disease 60
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group 60
Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study 59
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy 59
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials 59
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target 59
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation 59
Novel therapeutic targets for inflammatory bowel disease 59
Different Segmental Transit Time (TT) Through the Small Bowel May Affect Wireless Capsule (WC) Endoscopy 59
Response evaluation and safety of thiopurines in the treatment of inflammatory bowel diseases (IBD): safety and response evaluation. 59
Clinical Utility of the LeMann Index and Rutgeerts Score to Predict Postoperative Course of Crohn's Disease: A Retrospective Single-Center Cohort Study 59
Psychological Functioning of Patients With Inflammatory Bowel Disease 58
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy 58
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment 58
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease 58
Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease 57
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients 57
Totale 7.541
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.922
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 128.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.770 0 0 0 0 0 898 381 197 614 337 15 328
2021/20221.513 99 15 65 306 12 8 64 197 152 203 310 82
2022/20233.348 616 152 388 350 208 281 16 256 544 324 168 45
2023/20241.934 202 151 383 92 56 257 101 117 34 42 168 331
2024/20252.711 60 61 25 55 29 324 130 305 350 741 296 335
2025/20263.711 1.042 550 724 1.037 287 71 0 0 0 0 0 0
Totale 16.203